文献速递肿瘤 PET/CT

PSMA PET用于复发检测

PSMA PET for Detection of Recurrence.
PubMed 文献 · Semin Nucl Med · 2023-08-09

本文综述前列腺特异性膜抗原(PSMA)靶向PET/CT或PET/MRI在前列腺癌生化复发(BCR)检测中的应用。美国与欧洲指南推荐BCR时行CT、MRI和骨显像等常规影像,但这些方法在低PSA水平低体积复发时存在局限。PSMA PET在检测局部复发和转移方面显示优于常规影像的诊断性能,最新版美国国家综合癌症网络(NCCN)指南已纳入PSMA靶向PET/CT或PET/MRI用于BCR前列腺癌的定位。

要点

  • BCR时美欧指南推荐CT、MRI和骨显像等常规影像,但低PSA水平低体积复发检测受限。
  • PSMA PET在BCR检测局部复发和转移方面显示优于常规影像的诊断性能。
  • 最新版NCCN指南已纳入PSMA靶向PET/CT或PET/MRI用于BCR前列腺癌定位。

核心结论

  • PSMA靶向PET在BCR前列腺癌中显示优于常规影像的诊断性能,可指导个体化治疗决策并改善患者结局。

研究设计与样本

  • 本文为综述,检索范围与纳入方法原文未报告。

主要发现

  • BCR时CT、MRI和骨显像等常规影像在低PSA水平低体积复发检测中存在局限。
  • PSMA PET在检测局部复发和转移方面显示优于常规影像的诊断性能,即使在极低PSA水平亦如此。
  • 不同放射性核素标记的多种PSMA靶向放射性药物特性略有差异,但总体对前列腺癌具有相似的高灵敏度和特异度。

关键数值与推荐

  • 美国与欧洲指南推荐BCR时行CT、MRI和骨显像等常规影像。
  • 最新版NCCN指南已纳入PSMA靶向PET/CT或PET/MRI用于BCR前列腺癌的定位。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer (PC) is a significant health concern worldwide, with high incidence and mortality rates. Early and accurate detection and localization of recurrent disease at biochemical recurrence (BCR) is critical for guiding subsequent therapeutic decisions and improving patient outcomes. At BCR, conventional imaging consisting of CT, MRI, and bone scintigraphy are recommended by US and European guidelines, however, these modalities all bear certain limitations in detecting metastatic disease, particularly in low-volume relapse at low prostate-specific antigen (PSA) levels. Molecular imaging with PET/CT or PET/MRI using prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals has revolutionized imaging of PC. Particularly at BCR PC, PSMA PET has shown better diagnostic performance compared to conventional imaging in detecting local relapse and metastases, even at very low PSA levels. The most recent version of the National Comprehensive Cancer Network (NCCN) guideline has included PSMA-targeted PET/CT or PET/MRI for the localization of BCR PC. There are several different PSMA-targeting radiopharmaceuticals labeled with different radioisotopes, each with slightly different characteristics, but overall similar high sensitivity and specificity for PC. PSMA-targeted PET has the potential to significantly impact patient care by guiding personalized treatment decisions and thus improving outcomes in BCR PC patients.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Duan H, Iagaru A. PSMA PET for Detection of Recurrence. Semin Nucl Med. 2023. PMID: 37567795. doi:10.1053/j.semnuclmed.2023.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。